HIV medication-based urolithiasis
- PMID: 25852859
- PMCID: PMC4377784
- DOI: 10.1093/ckj/sfu008
HIV medication-based urolithiasis
Abstract
Drug-induced renal calculi represent 1-2% of all renal calculi. In the last decade, drugs used for the treatment of HIV-infected patients have become the most frequent cause of drug-containing urinary calculi. Among these agents, protease inhibitors (PIs) are well known to induce kidney stones, especially indinavir and atazanavir, and more recently darunavir. Urolithiasis attributable to other PIs has also been reported in clinical cases such as those during non-PI use. Antiretroviral drug-induced calculi deserve consideration because most of them are potentially preventable. This article summarizes the diagnosis, epidemiology, prevention and management of antiretroviral drug-induced urolithiasis.
Keywords: HIV; antiretroviral; renal failure; urolithiasis.
Figures
References
-
- Teichman JMH. Acute renal colic from ureteral calculus. N Engl J Med. 2004;350:684–693. - PubMed
-
- Trinchieri A. Epidemiological trends in urolithiasis: impact on our health care systems. Urol Res. 2006;34:151–156. - PubMed
-
- Lehr D. Clinical toxicity of sulfonamides. Ann N Y Acad Sci. 1957;69:417–447. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
